Longitude Capital
Overview
Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Entera Bio Ltd. | Aug 2026 | Private Placement | Co-investor |
| Quanta Therapeutics | Jun 2026 | Series D | Co-investor |
| cAMPfield Therapeutics | Jun 2026 | Series A | Co-investor |
| Endogenex | Mar 2026 | Series C Extension | Co-investor |
For institutional investors. Book with your work email.
Key People
Juliet Tammenoms Bakker
Co-Founder, Managing Director
Fran Morilak
Senior Partner
Trudy Vanhove
Venture Partner
Victoria Lai
Principal
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Longitude Capital based?
Longitude Capital is headquartered in Menlo Park, California, United States.
When was Longitude Capital founded?
Longitude Capital was founded in 2006.
How many portfolio companies does Longitude Capital have?
Longitude Capital has 51 portfolio companies in Caplight's dataset.
What are some companies in Longitude Capital's portfolio?
Recent investments visible on Caplight include Entera Bio Ltd., Quanta Therapeutics, cAMPfield Therapeutics, cAMPfield Therapeutics, Endogenex.
What was Longitude Capital's most recent investment?
Longitude Capital's most recent investment on Caplight was in Entera Bio Ltd. in 2026.
What sectors does Longitude Capital focus on?
Longitude Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Healthcare & Life Sciences, Enterprise Software, Consumer & Commerce, Enterprise Software, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure.
What company stages does Longitude Capital focus on?
Longitude Capital typically invests at the MultiStage stage.
What is Longitude Capital's AUM?
Longitude Capital's assets under management are estimated between $1.0B and $10.0B.